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global eradication of WPV 1 and 3. Only IPV will continue in a polio
eradicated world.
http://dx.doi.org/10.1016/j.ijid.2016.02.094
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Abstract: Adoption of new vaccines is critical to improve child
health overall and reduce child mortality. However, new vaccine
introduction has historically been delayed in developing coun-
tries due to multiple factors (lack of data, economic, logistical and
awareness factors). Recently, the Global Alliance for Vaccines and
Immunizations (GAVI) supported the Hib Initiative to accelerate
the introduction of Hib vaccines in developing countries, which
was very successful and led to introduction of Hib vaccine in all
GAVI eligible countries, as well asmany other countries around the
world. The strategy adopted by theHib Initiative addressed barriers
for vaccine introduction by focusing on three areas: communica-
tions to increase awareness about disease and vaccine; research to
answer key questions needed to support evidence-based decisions,
and long term program sustainability; and coordination with var-
ious stakeholders at global, regional and country levels to ensure
successful program implementation. The success of the Hib Initia-
tive provided a boost to new vaccine introduction, and the lessons
learned from this experience were very useful to support acceler-
ated introduction of the newer vaccines, including pneumococcal,
rotavirus and HPV vaccines.
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